Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

US Patent 11447553 · Granted Sep 20, 2022

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method of making afucosylated anti-FGFR2IIIB antibodies2025
Medical use of interferon-lambda for the treatment of fibrosis2024
B7-H4 antibodies and methods and use thereof2024
B7-H4 antibodies and methods of use thereof2023
Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected canc2023
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic2022
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic2022
B7-H4 antibodies and methods of use thereof2022
Afucosylated anti-FGFR2IIIB antibodies2022
Methods of treating conditions with antibodies that bind colony stimulating fact2021
NOPE for treatment of pathological muscle loss and weakness2020
Method of treating PVNS with anti-CSF1R antibodies2020